Non-coding RNA regulation of integrins and their potential as therapeutic targets in cancer
Conclusions and PerspectivesThis review examines the regulation of integrin genes by ncRNAs, provides and overview of their mechanism of action and highlights how exploitation of these discoveries is informing the development of novel chemotherapeutic agents in the treatment of cancer. MiRNA molecules have been the most extensively characterised and negatively regulate most integrin genes, classically regulating genes through binding to recognition sequences in the mRNA 3′-untranslated regions of gene transcripts. LncRNA mechanisms of action are now being elucidated and appea r to be more varied and complex, and may c...
Source: Cellular Oncology - December 13, 2022 Category: Cancer & Oncology Source Type: research
OrBITS: label-free and time-lapse monitoring of patient derived organoids for advanced drug screening
ConclusionOur findings validate that OrBITS, as a scalable, automated live-cell image analysis software, would facilitate the use of patient-derived organoids for drug development and therapy screening. The developed wet-lab workflow and software also has broad application potential, from providing a launching point for further brightfield-based assay development to be used for fundamental research, to guiding clinical decisions for personalized medicine. (Source: Cellular Oncology)
Source: Cellular Oncology - December 12, 2022 Category: Cancer & Oncology Source Type: research
Discovery of a small molecule ligand of FRS2 that inhibits invasion and tumor growth
ConclusionsOur results illustrate a phenotype-guided drug discovery strategy that identified a novel mechanism to repress FGFR-driven invasiveness and growth in human cancers. The here identified bioactive leads targeting FGF signaling and cell dissemination provide a novel structural basis for further development as a tumor agnostic strategy to repress FGFR- and FRS2-driven tumors. (Source: Cellular Oncology)
Source: Cellular Oncology - December 10, 2022 Category: Cancer & Oncology Source Type: research
Kavain ablates the radio-resistance of IDH-wildtype glioblastoma by targeting LITAF/NF- κB pathway
ConclusionIn mechanism, our results indicated that 1) the elevation of LITAF in GBM cells activates the NF- κB pathway to promote mesenchymal transition, and 2) kavain disturbs STAT6B/LITAF protein interaction and then expels LITAF from the nucleus. Therefore, we consider that kavain may be a potential candidate to develop an irradiation therapy adjuvant for GBM. (Source: Cellular Oncology)
Source: Cellular Oncology - December 5, 2022 Category: Cancer & Oncology Source Type: research
AKT-driven epithelial-mesenchymal transition is affected by copper bioavailability in HER2 negative breast cancer cells via a LOXL2-independent mechanism
ConclusionsWe provide evidence of a pivotal role of copper in AKT-driven EMT activation, acting independently of HER2 in TNBC cells and via a profound change in their metabolism. Our results support the use of copper-chelators as an adjuvant therapeutic strategy for TNBC. (Source: Cellular Oncology)
Source: Cellular Oncology - December 1, 2022 Category: Cancer & Oncology Source Type: research
Nucleotide sugar transporter SLC35A2 is involved in promoting hepatocellular carcinoma metastasis by regulating cellular glycosylation
ConclusionSLC35A2 plays important roles in promoting HCC metastasis by regulating cellular glycosylation modification and inducing the cell adhesive ability of HCC cells. (Source: Cellular Oncology)
Source: Cellular Oncology - December 1, 2022 Category: Cancer & Oncology Source Type: research
Targeting tumor-intrinsic PD-L1 suppresses the progression and aggressiveness of head and neck cancer by inhibiting GSK3 β-dependent Snail degradation
ConclusionThe discovery of MEIO targeting the tumor-intrinsic function of PD-L1 may prove particularly valuable for the development of novel and effective anticancer drug candidates for HNCs overexpressing PD-L1. (Source: Cellular Oncology)
Source: Cellular Oncology - November 28, 2022 Category: Cancer & Oncology Source Type: research
The LINC00152/miR-205-5p/CXCL11 axis in hepatocellular carcinoma cancer-associated fibroblasts affects cancer cell phenotypes and tumor growth
ConclusionOur data indicate that a LINC00152/miR-205-5p/CXCL11 axis in HCC CAFs can affect the proliferative and migrative abilities of HCC cells in vitro and HCC tumor growthin vivo. (Source: Cellular Oncology)
Source: Cellular Oncology - November 26, 2022 Category: Cancer & Oncology Source Type: research
Tumour-derived exosomal lncRNA SNHG16 induces telocytes to promote metastasis of hepatocellular carcinoma via the miR-942-3p/MMP9 axis
ConclusionTumour-derived exosomal LncSNHG16 modulates MMP9 via competitively binding to miR-942-3p in TCs, thus promoting the metastasis of HCC. (Source: Cellular Oncology)
Source: Cellular Oncology - November 25, 2022 Category: Cancer & Oncology Source Type: research
Correction to: Colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolution
(Source: Cellular Oncology)
Source: Cellular Oncology - November 24, 2022 Category: Cancer & Oncology Source Type: research
Single cell profiling of γδ hepatosplenic T-cell lymphoma unravels tumor cell heterogeneity associated with disease progression
ConclusionsOur study reveals heterogenous and dynamic tumor and microenvironment underlying pathogenesis of HSTCL and may contribute to identify novel targets for diagnosis and treatment of HSTCL in the future. (Source: Cellular Oncology)
Source: Cellular Oncology - November 22, 2022 Category: Cancer & Oncology Source Type: research
PD-1-CD28 fusion protein strengthens mesothelin-specific TRuC T cells in preclinical solid tumor models
ConclusionTogether, these results demonstrate the therapeutic potential of PD-1-CD28 co-expression in TRuC T cells to prevent PD-L1-induced T cell hypofunction. (Source: Cellular Oncology)
Source: Cellular Oncology - November 21, 2022 Category: Cancer & Oncology Source Type: research
IDH2, a novel target of OGT, facilitates glucose uptake and cellular bioenergy production via NF- κB signaling to promote colorectal cancer progression
ConclusionWild-type IDH2 reprogrammed glucose metabolism and bioenergetic production via the NF- κB signaling pathway to promote CRC development and progression.O-GlcNAcylation of IDH2 elevated the stability of IDH2 protein. And the axis of OGT-IDH2 played an essential promotive role in tumor progression, suggesting a novel potential therapeutic strategy in CRC treatment. (Source: Cellular Oncology)
Source: Cellular Oncology - November 19, 2022 Category: Cancer & Oncology Source Type: research
CEP55 3 ’-UTR promotes epithelial–mesenchymal transition and enhances tumorigenicity of bladder cancer cells by acting as a ceRNA regulating miR-497-5p
ConclusionsThese results suggest that a ceRNA regulatory network involving CEP55 upregulates PTHLH and HMGA2 expression by suppressing endogenous miR-497-5p. We unveiled a novel mechanism of BC metastasis, and could become novel therapeutics targets in BC. (Source: Cellular Oncology)
Source: Cellular Oncology - November 14, 2022 Category: Cancer & Oncology Source Type: research
TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4+Foxp3+ regulatory T cells
ConclusionThis study, therefore, provides clear experimental evidence that TNFR2 antagonistic antibody, TY101, can promote the death of Tregs, and this effect may be attributable to the antitumor effect of TNFR2 antagonistic antibody. (Source: Cellular Oncology)
Source: Cellular Oncology - November 12, 2022 Category: Cancer & Oncology Source Type: research
